SCHEMBL14406643

SCHEMBL14406643

CS(=O)(=O)CCC1CCN(C(=O)O)CC1

nearest known ligand 0.40

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.40
ATM Q13315 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.36
GPR119 Q8TDV5 4/20 0.35
ITGB3 P05106 5/20 0.35
ITGA2B P08514 5/20 0.35
GNAI3 P08754 2/20 0.35
GNAO1 P09471 2/20 0.35
GNAI1 P63096 2/20 0.35
DPP8 Q6V1X1 1/20 0.33
DPP7 Q9UHL4 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6650151 0.81 ALDH1A1 (0.38) ALDH1A1ATML3MBTL1
SCHEMBL16829654 0.81 ALDH1A1 (0.34) ALDH1A1ATML3MBTL1
SCHEMBL14406677 0.81 BRD4 (0.43) ALDH1A1ATMGPR119
SCHEMBL309779 0.79 GPR119 (0.56) GPR119
SCHEMBL3504427 0.79 ALDH1A1 (0.31) ALDH1A1ATM
SCHEMBL458216 0.78 GPR119 (0.38) ALDH1A1ATMGPR119
SCHEMBL12016032 0.77 GNAI3 (0.45) ITGB3ITGA2BGNAI3GNAO1GNAI1
SCHEMBL155583 0.77 EPHX2 (0.41) ALDH1A1L3MBTL1GNAI3GNAO1GNAI1
SCHEMBL4438764 0.76 GPR119 (0.44) ALDH1A1ATMGPR119ITGB3ITGA2B
SCHEMBL3132682 0.76 RAB9A (0.42) L3MBTL1GPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3790871-B1 FURIN INHIBITORS GLAXOSMITHKLINE IP DEV LTD (GB) 2024-01-24 EP disclosed
US-11773078-B2 Furin inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2023-10-03 US disclosed
US-20220315556-A1 FURIN INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2022-10-06 US disclosed
EP-3790871-A1 FURIN INHIBITORS GlaxoSmithKline Intellectual Property Development Limited (GB) 2021-03-17 EP disclosed
WO-2019215341-A1 FURIN INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2019-11-14 WO disclosed
CN-103755686-B The piperidyl with platelet aggregation inhibitory activity replaces 5-hydroxyryptophan derivative CHINA PHARMACEUTICAL UNIVERSITY (CN) 2016-05-11 CN disclosed
CN-103755686-A Piperidyl substituted 5-hydroxytryptophane derivatives with anti-platelet aggregation activity UNIV CHINA PHARMA 2014-04-30 CN disclosed
CN-101932580-B Imidazopyridine kinase inhibitors GLAXOSMITHKLINE LLC 2013-05-22 CN disclosed
EP-2162454-B1 IMIDAZOPYRIDINE KINASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2013-01-02 EP disclosed
CN-101932580-A Imidazopyridine kinase inhibitors GLAXOSMITHKLINE LLC 2010-12-29 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220315556-A1 FURIN INHIBITORS FURIN, TGFB1, PCSK7 ALDH1A1 3733/4885ATM 3778/4885L3MBTL1 3062/4885
US-11773078-B2 Furin inhibitors FURIN, TGFB1, PCSK7 ALDH1A1 3733/4885ATM 3778/4885L3MBTL1 3062/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.